CONTACT US
contact us
logotype
CONTACT US

Have a Project in Mind? Say Hi!

  • Mon - Sun: 10am - 10pm
  • 27 Division St, New York,
    NY 10002, USA​
HomeGrid 2 Columns
Grid 2 Columns
December 10, 2024
PR NeweswireBY admin

Qnovia, Inc. Raises $16 Million in Series B Financing to Advance Lead Asset RespiRx™ Nicotine Inhaler as a Prescription Smoking Cessation Therapy

READ MORE
October 25, 2024
ForbesBY admin

This Startup Has A New Way To Quit Smoking. Will this be the one that works?

READ MORE
October 21, 2024
PR NeweswireBY admin

Qnovia, Inc. CEO Speaks at FDA and NIH Public Meeting to Encourage Innovation of Smoking Cessation Treatment Options

READ MORE
October 2, 2024
Drug Delivery BusinessBY admin

Qnovia wins FDA nod for nicotine inhaler as smoking cessation therapy

READ MORE
October 1, 2024
PR NeweswireBY admin

Qnovia, Inc. announces FDA clearance of IND application for lead asset RespiRx™ Nicotine Inhaler as a prescription smoking cessation therapy

READ MORE
April 9, 2024
Business WireBY admin

Qnovia, Inc. Announces the Appointment of Four New Members to its Scientific Advisory Board

READ MORE
#side-panel.side-panel {width: 500px;}#side-panel.side-panel .side-panel_sidebar {padding: 70px 0px 50px 60px;background-color: #FFFFFF;} Qnovia